Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Identification of progressors in osteoarthritis by combining biochemical and MRI based markers. / Dam, Erik Bjørnager; Loog, Marco; Christiansen, Claus; Byrjalsen, Inger; Folkesson, Jenny Maria; Nielsen, Mads; Qazi, Arish Asif; Pettersen, Paola; Garnero, Patrick; Karsdal, Morten A.

I: Arthritis Research & Therapy, Bind 11, Nr. 4, 24.07.2009, s. 1-11.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Dam, EB, Loog, M, Christiansen, C, Byrjalsen, I, Folkesson, JM, Nielsen, M, Qazi, AA, Pettersen, P, Garnero, P & Karsdal, MA 2009, 'Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.', Arthritis Research & Therapy, bind 11, nr. 4, s. 1-11. https://doi.org/10.1186/ar2774

APA

Dam, E. B., Loog, M., Christiansen, C., Byrjalsen, I., Folkesson, J. M., Nielsen, M., Qazi, A. A., Pettersen, P., Garnero, P., & Karsdal, M. A. (2009). Identification of progressors in osteoarthritis by combining biochemical and MRI based markers. Arthritis Research & Therapy, 11(4), 1-11. https://doi.org/10.1186/ar2774

Vancouver

Dam EB, Loog M, Christiansen C, Byrjalsen I, Folkesson JM, Nielsen M o.a. Identification of progressors in osteoarthritis by combining biochemical and MRI based markers. Arthritis Research & Therapy. 2009 jul 24;11(4):1-11. https://doi.org/10.1186/ar2774

Author

Dam, Erik Bjørnager ; Loog, Marco ; Christiansen, Claus ; Byrjalsen, Inger ; Folkesson, Jenny Maria ; Nielsen, Mads ; Qazi, Arish Asif ; Pettersen, Paola ; Garnero, Patrick ; Karsdal, Morten A. / Identification of progressors in osteoarthritis by combining biochemical and MRI based markers. I: Arthritis Research & Therapy. 2009 ; Bind 11, Nr. 4. s. 1-11.

Bibtex

@article{dc844410260211df8ed1000ea68e967b,
title = "Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.",
abstract = "At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.",
author = "Dam, {Erik Bj{\o}rnager} and Marco Loog and Claus Christiansen and Inger Byrjalsen and Folkesson, {Jenny Maria} and Mads Nielsen and Qazi, {Arish Asif} and Paola Pettersen and Patrick Garnero and Karsdal, {Morten A}",
year = "2009",
month = jul,
day = "24",
doi = "10.1186/ar2774",
language = "English",
volume = "11",
pages = "1--11",
journal = "Arthritis Research & Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "4",

}

RIS

TY - JOUR

T1 - Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.

AU - Dam, Erik Bjørnager

AU - Loog, Marco

AU - Christiansen, Claus

AU - Byrjalsen, Inger

AU - Folkesson, Jenny Maria

AU - Nielsen, Mads

AU - Qazi, Arish Asif

AU - Pettersen, Paola

AU - Garnero, Patrick

AU - Karsdal, Morten A

PY - 2009/7/24

Y1 - 2009/7/24

N2 - At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.

AB - At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.

U2 - 10.1186/ar2774

DO - 10.1186/ar2774

M3 - Journal article

C2 - 19630944

VL - 11

SP - 1

EP - 11

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

SN - 1478-6354

IS - 4

ER -

ID: 18339138